MDM2 and neoplasm: The DTC staple, structurally validated, induced the formation of and stabilized a productive α-helical conformation of PMI – a dual-specificity peptide antagonist of MDM2 and MDMX, enabling it to traverse the cell membrane and kill tumor cells by reactivating the p53 pathway.